Brief: Absci Announces First Participants Dosed In Phase 1/2A Headline Trial

Dec 4 (Reuters) - Absci Corp ABSI.O:

ABSCI ANNOUNCES FIRST PARTICIPANTS DOSED IN PHASE 1/2A HEADLINE™ TRIAL OF AI-DESIGNED ANTIBODY ABS-201™ FOR ANDROGENETIC ALOPECIA

ABSCI CORP: INTERIM DATA ANTICIPATED IN SECOND HALF OF 2026

ABSCI CORP - PHASE 2 DEVELOPMENT OF ABS-201 IN ENDOMETRIOSIS PLANNED FOR Q4 2026

Source text: ID:nGNXR58y

Further company coverage: ABSI.O

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on AbSci

See all news